← Back to Search

PCD Individuals confirmed positive for DNAI1 for Primary Ciliary Dyskinesia

N/A
Recruiting
Research Sponsored by ReCode Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disease.

Eligible Conditions
  • Primary Ciliary Dyskinesia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of PCD individuals with DNAI1 mutation identified through genetic testing
Secondary outcome measures
Number of Health Care Provider (HCP) and their referred individuals eligible for genetic testing for PCD
Proportion of PCD individuals with DNAI1 mutations and number of patients with mutations in other PCD genes of interest

Trial Design

3Treatment groups
Experimental Treatment
Group I: PCD Individuals confirmed positive for other genotypes of interestExperimental Treatment1 Intervention
Group II: PCD Individuals confirmed positive for DNAI1Experimental Treatment1 Intervention
Group III: Individuals negative for a gene causing PCDExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

ReCode TherapeuticsLead Sponsor
3 Previous Clinical Trials
91 Total Patients Enrolled
Sano GeneticsIndustry Sponsor
ReverbaUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials
2023. "A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06172374.
All > Sacramento
~100 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top